MedTrace Logo

Sildenafil for Secondary Pulmonary Hypertension Due to Valvular Disease

NCT00862043 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-09-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the clinical efficacy of the mid-term treatment with sildenafil in patients with persistent moderate or severe pulmonary hypertension (PH) after a heart valve intervention.

Conditions

  • Pulmonary Hypertension
  • Valvular Heart Disease

Interventions

DRUG

Sildenafil Citrate

40 mg t.i.d.

DRUG

Placebo

Placebo t.i.d.

Sponsors & Collaborators

  • Instituto de Salud Carlos III

    collaborator OTHER_GOV

  • Fundación de Investigación en Red en Enfermedades Cardiovasculares

    collaborator OTHER

  • Hospital General Universitario Gregorio Marañon

    lead OTHER

Principal Investigators

  • Javier Bermejo, MD, PhD · Hospital General Universitario Gregorio Maranon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00862043 on ClinicalTrials.gov